Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 292 results for "Mk 5172"

The Combination of Grazoprevir (MK-5172), an NS3 Inhibitor, an...

65th Annual Meeting of the American Association for the Study of Liver Diseases Boston, MA Nov 7-11 2014 Reported by Jules Levin AASLD 2014 Nov 7-11 Boston Fred Lahser1, Karin Bystol1, Stephanie Curry1, Patricia McMonagle1, Rong Liu1, Ellen ... National AIDS Treatment Advocacy Project, 1 week ago

5 images for Mk 5172

MDLinx, 1 week ago
MDLinx, 1 week ago
Citybizlist, 1 month ago
Jutia Group, 1 month ago
Securities Technology Monitor, 1 month ago

Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous

The Lancet, Early Online Publication, 11 November 2014 Eric Lawitz, Edward Gane, Brian Pearlman, Edward Tam, Wayne Ghesquiere, Dominique Guyader, Laurent Alric, Jean-Pierre Bronowicki, Laura Lester, William Sievert, Reem Ghalib, Luis Balart, ...
 National AIDS Treatment Advocacy Project1 week ago Excellent Results for 12 and 18 Weeks of Merck's Dual Hep C Regimen  AIDSmeds1 week ago Merck (MRK) Updates on MK-5172/MK-8742 Phase 2  Wall Street Business Network1 week ago Efficacy and safety of MK-5172 and MK-8742 ± RIBAVIRIN IN Hcv Gt1 Infected Patients with cirrhosis or previous null reSPonse: FINAL RESULTS OF the C-WORTHY Study (PARTS A AND B)  National AIDS Treatment Advocacy Project1 week ago
[x]  
Bioresearch Online

Merck to Present New Data from Clinical Studies Evaluating Investigational Hepatitis C Treatment Grazoprevir/Elbasvir MK-5172/MK-8742 at the 65th...

Merck to Present New Data from Clinical Studies Evaluating Investigational Hepatitis C Treatment Grazoprevir/Elbasvir MK-5172/MK-8742 at the 65th American Association for the Study of Liver Diseases Annual Meeting By a News Reporter-Staff News ...
 4 Traders1 month ago Merck Posts Data For Triple-Drug HCV Regimen  Bioresearch Online1 week ago MERCK : Announces Results from Phase 2 Study of Investigational Chronic Hepatitis C Treatment Grazoprevir/Elbasvir in Genotype 1 Infected Treatment-Nave and Difficult-to-Cure Patients  4 Traders1 week ago Merck & Co.???s Investigational Hepatitis C Treatment Grazoprevir/Elbasvir In Combination With A Nucleotide Inhibitor (C-SWIFT Study) Presented At The Liver Meeting??  BioSpace2 weeks ago
[x]  

Drug Delivery: Lessons to Be Learnt From Leishmania Studies

Heyneman D. Immunology of leishmaniasis. Bull. World Health Organ. 44(4), 499514 (1971). Antoine JC, Prina E, Lang T et al. The biogenesis and properties of the parasitophorous vacuoles that harbour Leishmania in murine macrophages. Trends ...
 Medscape3 days ago

Investigational HCV Combo Delivers in Differing Groups

Gastroenterology Published: Nov 16, 2014 BOSTON -- A new study suggests that some subgroups of patients with hepatitis C (HCV) infection can achieve sustained virologic responses (SVR) in as short as 4 weeks using an aggressive, investigational ...
 MedPage Today1 week ago Shorter Treatment Shows Promise With Investigative HCV Agents  MedPage Today1 week ago

Investigative Combo Pill Effective Against HCV Infection

Meeting Coverage Published: Nov 13, 2014 This report is part of a 12-month Clinical Context series. ByEd Susman , Contributing Writer, MedPage Today BOSTON -- An investigational combination treatment appears to allow difficult-to-treat ...
 MedPage Today1 week ago

C-WORTHy: Grazoprevir/elbasvir regimen yielded high SVR rates in patients with HCV genotype 1

BOSTON — A number of patients with hepatitis C virus genotype 1 infection, with and without cirrhosis, and patients co-infected with HIV and HCV, achieved sustained virologic response at 12 weeks when treated grazoprevir and elbasvir, with or ...
 Orthopedics Today1 week ago C-WORTHy: Grazoprevir/elbasvir achieved SVR12 in more than 90% of patients  Orthopedics Today1 week ago

Do Merck's Recent Hepatits C Trial Results Weaken Its Position?

Merck (NYSE:MRK) recently released some data from clinical trials of a triple-pill regimen for the treatment of treatment-naive group of cirrhotic patients. Cirrhotic patients refer to individuals with significant liver scarring, or the replacement ...
 Trefis1 week ago

Merck's triple-therapy hepatitis C regimen shows sub-optimal efficacy

US pharma giant Merck & Co (NYSE: MRK) has admitted that interim data from its triple-therapy regimen in hepatitis C has shown sub-optimal efficacy. The data from the C-SWIFT study explored the potential of a candidate triple-therapy regimen ...
 Pharma Letter1 week ago

Merck Reports Interim Data on Hepatitis C Virus Drug

Merck & Co. Inc. ( MRK ) presented interim data from a proof-of-concept (C-SWIFT) study on its fixed-dose combination regimen grazoprevir/elbasvir (MK-5172/MK-8742, MK-5172A) plus Gilead's ( GILD ) Sovaldi (sofosbuvir a nucleotide inhibitor) for ...
 Yahoo! Finance2 weeks ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less